Showing results (381-390 of 445) with videos related to
Sort By:
Pageof 45
AJNR. American Journal of Neuroradiology|June 17, 2008
White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS studyC Ryberg, E Rostrup, K Sjöstrand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke, Emily K Bergsland, David P Ryan, et al.Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 13, 2009
Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS studyS Benisty, A A Gouw, R Porcher, et al.Journal of Neurology|September 26, 2006
Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS studyA A Gouw, W M Van der Flier, E C W van Straaten, et al.Advances in Radiation Oncology|May 11, 2026
Acute Toxicity From Short-Course Radiation Therapy for Rectal Cancer: A Single-Institution ExperienceShane S Neibart, Katie N Lee, Yu-Hui Chen, et al.Neurology|May 6, 2011
Incident lacunes influence cognitive decline: the LADIS studyH Jokinen, A A Gouw, S Madureira, et al.Neurology|March 19, 2008
Association of gait and balance disorders with age-related white matter changes: the LADIS studyH Baezner, C Blahak, A Poggesi, et al.The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2011
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan, L S Blaszkowsky, P C Enzinger, et al.Pageof 45